An Open-label, Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
Latest Information Update: 05 Aug 2024
At a glance
- Drugs Dostarlimab (Primary) ; Niraparib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 01 Aug 2024 Planned End Date changed from 1 Jun 2027 to 1 Jun 2025.
- 06 Jun 2023 Status changed to discontinued, according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results (n=10) presented at the 59th Annual Meeting of the American Society of Clinical Oncology